System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Vincent Camus is an expert in Hematology at Centre Henri Becquerel (France). As of October 2026, ScienceLeadR ranks Vincent Camus in the top 1% of experts worldwide for Lymphoma and Lymphoproliferative Disorders. Vincent Camus has authored 349 publications, the most recent in 2026, and is an investigator in 34 clinical trials, 11 of them ongoing. SLR score: 1,298 (community average: 125). How the SLR is computed.

LeadR Profile

Vincent Camus Centre Henri Becquerel France
1 298 ScienceLeadR Reputation 1298

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Neurology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2026
Source: PubMed

Centre Henri Becquerel

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 349

Citations

Citations: 12 685 1st author: 50 Last author: 58 Unique author: 4

Main journals

Blood 17
Blood Adv 13
Alzheimers Dement 11
Clin Case Rep 10
Encephale 9

Best Journals

J Clin Oncol 3
JAMA 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Potential Benefit of Ruxolitinib in Suspected Ocular and Neurological Transplant-Associated Thrombotic Microangiopathy After Allogeneic Stem Cell Transplantation: A Case Report and Review.
PMID 42819691 — thrombotic microangiopathies, cells, microscopy, electron, scanning transmission, stem cells, transplants, cell transplantation, stem cell transplantation, transplantation		Clin Case Rep20260
PD-L2 is associated with lineage-related transcriptional programs distinct from PD-L1 in primary mediastinal large B-cell lymphoma.
PMID 42386908 — cells, lymphoma, b-cell, lymphoma, leukemia, ligands, b-lymphocytes		Leukemia20260
Methodological approaches to account for assay changes in longitudinal biomarker analysis: insights from Alzheimer's blood biomarkers in the MEMENTO cohort.
PMID 42265779 — research design, blood, alzheimer disease, biomarkers		Alzheimers Res Ther20260
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.
PMID 42118857 — cells, lymphoma, b-cell, lymphoma, neoplasms, positron emission tomography computed tomography, tumor burden, risk factors, therapeutics, b-lymphocytes		Blood Adv20260
Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.
PMID 42099680 — cells, lymphoma, b-cell, lymphoma, therapeutics, t-lymphocytes, b-lymphocytes, prognosis, car-t cell		Hemasphere20260

Clinical Studies 34

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 12 Study Chair: 1 Study Director: 1

By phase:

N/A 18
Phase 3 7
Phase 2 6
Phase 1/Phase 2 2
Early Phase 1 1

By status:

Completed 17
Recruiting 9
Active not recruiting 3
Terminated 3
Not yet recruiting 1
Unknown 1

By type:

Interventional 30
Observational 4

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 5
multicentric5to9 1
multicentricup10 19

Main Topics

Cohort/Consortium Investigators 15

Ongoing Clinical Trials

11 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Proof of Concept for Real time Multicentric Monitoring of MRD by PET and ctDNA in Aggressive B Cell Lymphomas
NCT07514715 — cells, blood, circulating tumor dna, lymphoma, b-cell, lymphoma, positron-emission tomography, neoplasms, neoplasm, residual, therapeutics, hematologic tests, dna, b-lymphocytes		N/ANot yet recruiting2026
PLATFORM A PLATFORM TRIAL EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMAS
2024-514954-63-00 — cells, pharmaceutical preparations, lymphoma, therapeutics, lymphoma, t-cell, peripheral, t-lymphocytes, lymphoma, t-cell		Phase 1/Phase 2Recruiting2025
A Platform Trial Evaluating New Drugs or Combination in R R Peripheral T cell Lymphomas
NCT07018752 — cells, safety, pharmaceutical preparations, lymphoma, azacitidine, therapeutics, lymphoma, t-cell, peripheral, t-lymphocytes, lymphoma, t-cell		Phase 1/Phase 2Recruiting2025
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
NCT06522737 — cells, immunoblastic lymphadenopathy, lymphadenopathy, lymphoma, phenotype, solutions, capsules, lymphoma, t-cell, peripheral, bendamustine hydrochloride, infusions, intravenous, t-lymphocytes, lymphoma, t-cell		Phase 3Recruiting2025
Circulating Tumor DNA Sequencing in Patients With Peripheral T cell Lymphomas
NCT06089941 — cells, high-throughput nucleotide sequencing, whole genome sequencing, blood, circulating tumor dna, lymphoma, neoplasms, genome, diagnosis, therapeutics, lymphoma, t-cell, peripheral, t-lymphocytes, dna, prospective studies, lymphoma, t-cell		N/AActive not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS